Armistice Capital’s Cardiff Oncology CRDF Stock Holding History

Armistice Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-82,928	Closed	-$103K	–	87
2019 Q4	$103K	Buy	+82,928	New	+$118K	0.01%	71

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Armistice Capital's CRDF Position: Q1 2020 in Review

Armistice Capital sold out of Cardiff Oncology (CRDF) in Q1 2020, closing a stake of 82,928 shares — an estimated $103K sold.

Armistice Capital first reported a position in CRDF in Q4 2019 and held it in 1 quarter. The position peaked at $103K in Q4 2019. 18 funds tracked by Wall St. Rank hold CRDF as of Q1 2020.

Armistice Capital reported no remaining Cardiff Oncology position as of Q1 2020 after selling out during the quarter.
Armistice Capital sold 82,928 Cardiff Oncology shares in Q1 2020, an estimated $103K.
Armistice Capital first reported a position in Cardiff Oncology in Q4 2019 and held it in 1 quarter.
Armistice Capital's Cardiff Oncology position peaked at $103K in Q4 2019.
18 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2020.

Based on Armistice Capital's 13F filing for Q1 2020, filed 15 May 2020.